作者
Sonya Youngju Park, Sae Jung Na, Meena Kumar, Camila Mosci, Mirwais Wardak, Norman Koglin, Santiago Bullich, Andre Mueller, Mathias Berndt, Andrew W Stephens, Yong Mee Cho, Hanjong Ahn, Sun Young Chae, Hye Ok Kim, Dae Hyuk Moon, Sanjiv S Gambhir, Erik S Mittra
发表日期
2020/10/15
期刊
Clinical Cancer Research
卷号
26
期号
20
页码范围
5380-5387
出版商
American Association for Cancer Research
简介
Purpose
(4S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) is a radiopharmaceutical for PET imaging of system xC− activity, which can be upregulated in prostate cancer. We present data on the first evaluation of patients with newly diagnosed or recurrent prostate cancer with this radiopharmaceutical.
Experimental Design
Ten patients with primary and 10 patients with recurrent prostate cancer were enrolled in this prospective multicenter study. After injection of 300 MBq of 18F-FSPG, three whole-body PET/CT scans were obtained. Visual analysis was compared with step-section histopathology when available as well as other imaging studies and clinical outcomes. Metabolic parameters were measured semiquantitatively. Expression levels of xCT and CD44 were evaluated by IHC for patients with available tissue samples.
Results
18F-FSPG …
学术搜索中的文章
SY Park, SJ Na, M Kumar, C Mosci, M Wardak… - Clinical Cancer Research, 2020